PMID- 38022404
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 1920-454X (Electronic)
IS  - 1920-4531 (Print)
IS  - 1920-4531 (Linking)
VI  - 14
IP  - 6
DP  - 2023 Dec
TI  - Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic 
      Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
PG  - 518-528
LID - 10.14740/wjon1685 [doi]
AB  - BACKGROUND: The emergence of olaparib, a poly (adenosine diphosphate 
      (ADP)-ribose) polymerase (PARP) inhibitor to treat metastatic 
      castration-resistant prostate cancer (mCRPC), created a measurable clinical 
      question on whether the agent positively influences the treatment outcomes and 
      acceptable safety factors. The objective was to elaborate on the efficacy and 
      safety of olaparib-added regimens in treating mCRPC patients as compared to the 
      established guideline. METHODS: The literature search was performed on several 
      scientific databases, e.g., PubMed, Cochrane, and ScienceDirect, by applying the 
      Boolean Term method. Statistical and risk of bias (RoB) analyses were calculated 
      through RevMan 5.4.1. to investigate our outcomes, i.e., progression-free 
      survival (PFS) and overall survival (OS) with the reported adverse effects (AEs). 
      These outcomes were presented in hazard ratio (HR) and risk ratio (RR). RESULTS: 
      Three trials consisting of 1,325 individuals with comparable baseline 
      characteristics were investigated. The meta-analysis showed that introducing 
      olaparib into the regimens significantly improved the PFS (HR 0.59 (0.48 - 0.73); 
      P < 0.05), which disclosed even better outcomes among mutated homologous 
      recombinant repair (HRR) and ataxia-telangiectasia mutated (ATM) gene (HR 0.43 
      (0.30 - 0.62); P < 0.05) in 95% confidence interval (CI). Furthermore, similar 
      outcomes were observed in OS analysis (HR 0.81 (0.67 - 0.99); P < 0.05), despite 
      olaparib group disclosed higher AEs rate with insignificant difference in 
      mortality rate. CONCLUSION: The efficacy and safety of olaparib-added regimens in 
      mCRPC patients need to be explored more extensively in trials because they are 
      beneficial, particularly among HRR-mutated individuals.
CI  - Copyright 2023, Warli et al.
FAU - Warli, Syah Mirsya
AU  - Warli SM
AUID- ORCID: 0000-0002-8339-1072
AD  - Department of Urology, Universitas Sumatera Utara Hospital, Universitas Sumatera 
      Utara, Medan, Indonesia.
AD  - Division of Urology, Department of Surgery, Faculty of Medicine, Universitas 
      Sumatera Utara-Haji Adam Malik General Hospital, Medan, Indonesia.
FAU - Velaro, Adrian Joshua
AU  - Velaro AJ
AUID- ORCID: 0000-0002-5871-6728
AD  - Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, 
      Indonesia.
FAU - Firsty, Naufal Nandita
AU  - Firsty NN
AUID- ORCID: 0000-0003-1668-6660
AD  - Department of Surgery, Faculty of Medicine, Universitas Sumatera Utara, Medan, 
      Indonesia.
FAU - Tala, Zaimah Zulkarnaini
AU  - Tala ZZ
AUID- ORCID: 0000-0001-7910-4117
AD  - Department of Nutrition, Faculty of Medicine, Universitas Sumatera Utara, Medan, 
      Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20231021
PL  - Canada
TA  - World J Oncol
JT  - World journal of oncology
JID - 101564097
PMC - PMC10681786
OTO - NOTNLM
OT  - Castration-resistant prostate cancer
OT  - HRR mutation
OT  - Olaparib
OT  - PARP
OT  - mCRPC
COIS- None to declare.
EDAT- 2023/11/29 18:43
MHDA- 2023/11/29 18:44
PMCR- 2023/10/21
CRDT- 2023/11/29 15:22
PHST- 2023/08/01 00:00 [received]
PHST- 2023/09/25 00:00 [accepted]
PHST- 2023/11/29 18:44 [medline]
PHST- 2023/11/29 18:43 [pubmed]
PHST- 2023/11/29 15:22 [entrez]
PHST- 2023/10/21 00:00 [pmc-release]
AID - 10.14740/wjon1685 [doi]
PST - ppublish
SO  - World J Oncol. 2023 Dec;14(6):518-528. doi: 10.14740/wjon1685. Epub 2023 Oct 21.